DexCom (DXCM) Stock Rating Maintained, Price Target Lowered | DXCM Stock News

Author's Avatar
May 02, 2025
Article's Main Image

DexCom (DXCM, Financial), a leader in glucose monitoring systems, recently saw its stock price target adjusted by Piper Sandler. Noted analyst Matt O'Brien maintained his "Overweight" rating on the stock, indicating continued confidence in the company's performance.

The price target for DexCom (DXCM, Financial) was lowered from $100.00 USD to $90.00 USD, reflecting a 10% decrease. This adjustment comes as part of Piper Sandler's latest assessment of the stock, reflecting revised market conditions and the company's outlook.

The decision to maintain the "Overweight" rating while lowering the price target suggests that Piper Sandler sees potential for growth in DexCom (DXCM, Financial) despite the revised price expectations. Investors should take note of these developments when considering their positions in the stock.

Overall, DexCom (DXCM, Financial) continues to hold an "Overweight" rating, indicating that it is expected to outperform the average return of stocks in the same sector. As the market evolves, stakeholders and potential investors should stay informed on further updates regarding DexCom's performance.

Wall Street Analysts Forecast

1918343720403628032.png

Based on the one-year price targets offered by 25 analysts, the average target price for DexCom Inc (DXCM, Financial) is $99.44 with a high estimate of $115.00 and a low estimate of $80.00. The average target implies an upside of 23.27% from the current price of $80.67. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.

Based on the consensus recommendation from 27 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $176.41, suggesting a upside of 118.68% from the current price of $80.67. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.